Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept
- Development stage
- Approved
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal, Intravenous
01
Overview
Aflibercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor. It is composed of portions of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. Aflibercept functions as a soluble decoy receptor with high affinity for VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing these ligands from binding to their native receptors on the surface of endothelial cells. This inhibition suppresses abnormal blood vessel formation and vascular permeability associated with diseases such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion-associated macular edema, and metastatic colorectal cancer. Aflibercept was developed by Regeneron Pharmaceuticals in collaboration with Sanofi for oncology indications and Bayer for ophthalmic indications[1][7].
- Brand names
- EyleaZaltrap
- Other names
- 阿柏西普ziv-aflibercept阿帕西普阿佰西普单抗
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept.